ALK and non-small cell lung carcinoma: Concerning DFS, Paik et al. reported a median DFS of 76.4 months in ALK-positive and 71.3 months in ALK-negative (EGFR status unknown) cases (p = 0.66) in resected stage I–III NSCLC patients.